At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 756 enrolled
Drug / intervention
AR-13324 Ophthalmic Solution 0.02% +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-masked, Randomized, Multi-center, Active-controlled, Parallel, 12-month Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-13324 Ophthalmic Solution, 0.02% q.d. and b.i.d. Compared to Timolol Maleate Ophthalmic Solution, 0.5% b.i.d. in Patients With Elevated Intraocular Pressure
In Brief
A Phase 3 clinical trial evaluating AR-13324 Ophthalmic Solution 0.02%, Timolol maleate Ophthalmic Solution 0.5% BID, and 2 other interventions for Ocular Hypertension and Open-angle Glaucoma. Completed, enrolled 756 participants across 1 site.
Detailed Summary
Evaluation of the ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOcular Hypertension, Open-angle Glaucoma
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJul 2014
First PostedAug 2014
Primary CompletionMar 2016
TodayJul 2026
First PostedAug 4, 2014
Enrollment StartJul 1, 2014
Primary CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.9 years ago
Interventions
AR-13324 Ophthalmic Solution 0.02%drug
1 drop once daily (QD), PM, OU
Timolol maleate Ophthalmic Solution 0.5% BIDdrug
1 drop BID, AM/PM, OU
Placeboother
1 drop QD, AM, OU
AR-13324 Ophthalmic Solution 0.02% BIDdrug
1 drop BID, AM/PM, OU